A retrospective cohort analysis of plasma TAT level trends and adverse pregnancy outcomes in early pregnancy patients with newly diagnosed VTE

Table 2 Results of multivariate analysis

Variables	Non-adjusted Model (OR,95%CI)	Minimally-adjusted Model (OR,95%CI)	Fully-adjusted Mode (OR,95%CI)
Continuous measures
TATp1	1.00 (0.89, 1.13)	1.01 (0.89, 1.14)	0.97 (0.84, 1.13)
TATp1	P = 0.945	P = 0.924	P = 0.719
TATp2	0.76 (0.66, 0.88)	0.77 (0.66, 0.89)	0.66 (0.53, 0.83)
TATp2	P = 0.0003*	P = 0.0007	P = 0.0003
TATp2-1	0.73 (0.62, 0.86)	0.73 (0.61, 0.86)	0.62 (0.47, 0.80)
TATp2-1	P = 0.0002	P = 0.0003	P = 0.0004
TATp2-1 tertiles
Low	Reference	Reference	Reference
Middle	0.45 (0.15, 1.33)	0.42 (0.13, 1.35)	0.38 (0.08, 1.75)
Middle	P = 0.149	P = 0.146	P = 0.214
High	0.13 (0.04, 0.42)	0.13 (0.04, 0.42)	0.07 (0.02, 0.33)
High	P = 0.0005	P = 0.0008	P = 0.0007
P for trend	0.0005	0.0007	0.0006

TATp1: Initial measurement was performed after VTE identified in first trimester, TATp2: second measurement was conducted during second trimester. TATp2-1: TAT change between TATp2 and TATp1.Non-adjusted Model: not adjusted for other covariant. Minimally-adjusted model: adjusted for age and education level. Fully-adjusted model: adjusted for age, education level, number of pregnancies, number of births, BMI, delivery methods, abnormal fetal position, gestational diabetes, gestational hypertension, pre-eclampsia, uterine fibroids, assisted reproduction, thyroid diseases, and thrombophilia. OR: odds ratio; CI: confidence interval

ISSN: 1477-9560